Skip to main content

Topic

Patents

824 published works

  1. Spicy IP

    General Comment on the IPO’s Draft Pharmaceutical Guidelines (2026)

    By Ambika Aggarwal

    A few days ago, we had informed our readers that they could participate in the open call for comments and suggestions on the Draft Guidelines for Examination of Patent Applications…

  2. Lathrop GPM

    Federal Circuit Decision Affirms Written Description Support for Broad Crystalline Salt Genus Claims

    By Lathrop GPM

    In a precedential ruling on August 31, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a District of Delaware judgment that the claims of three Exelixis patents…

  3. Spicy IP

    SpicyIP Tidbit: All Eyes on Kerala HC’s Final Hearing in the Ribociclib Matter Today

    By SpicyIP

    image from here [This post is authored by Rishabh Upadhyay. Rishabh is an LL.M. candidate at the Faculty of Law, Delhi University, having completed his undergraduate legal studies at the…

  4. The IPKat

    G1/25: What are the consequences?

    By Dr Rose Hughes

    Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are…

  5. Imagine That IP Law Blog

    Aligning IP Strategy with Business Reality: A Guide to Patent Portfolio Reviews

    By Alok A. Parikh

    A company may spend millions of dollars prosecuting and maintaining a patent portfolio designed around products, markets, and competitive threats identified five or ten years ago. The portfolio may contain…

  6. Chicago IP Litigation

    Court Denies Motion to Dismiss DTSA Claim Alleging Former Scientist Brought BTK Degrader Trade Secrets to Competitor

    By R. David Donoghue

    AbbVie Inc. v. BeiGene, LTD., et al., No. 24-cv-8167, (N.D. Ill. May 12, 2026) (Cummings, J.). Judge Cummings denied defendants’ Fed. R. Civ. P. 12(b)(6) motion to dismiss AbbVie’s Defend…

  7. Spicy IP

    SpicyIP Tidbit: CGPDTM Calls for Comments and Suggestions on New Draft Pharma and Biotech Patent Application Guidelines (2026)

    By Ambika Aggarwal

    In the time of this oncoming monsoon, it feels like its raining draft guidelines from the Controller General’s office! The office of the Controller General of Patents, Designs and Trademarks…

  8. Government and Public Policy

    Colombia Makes the Case for Rethinking Patent Exclusivity (and for Considering Prizes)

    By Simon Lester

    In mid-July, Colombia submitted a communication for discussion in the TRIPS Council entitled "A Better Trip: Autonomous Examination of TRIPS Prerogatives, and Existing Examples." The communication includes some interesting and…

  9. Founders Legal Blog

    Claude’s AI Watermark and the Patent Risks Founders Should Understand

    By Yuri L. Eliezer

    Claude’s AI Watermark and the Patent Risks Founders Should Understand by Yuri L. Eliezer Claude’s AI Watermark and the Patent Risks Founders Should Understand Claude’s AI watermark is not a…

  10. Patentology Blog

    The Aristocrat Effect – Subject Matter Objections at the Australian Patent Office

    By Mark Summerfield

    On 16 September 2025, the Full Federal Court of Australia handed down its decision in Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2025] FCAFC 131, holding Aristocrat’s claims…